{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:48:28Z","timestamp":1768531708110,"version":"3.49.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11433-6","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:25:13Z","timestamp":1768213513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sugar transporter SLC45 gene family members: roles in malignant tumors and research progress"],"prefix":"10.1007","volume":"53","author":[{"given":"Yuance","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"11433_CR1","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s00424-017-2024-9","volume":"469","author":"O Vitavska","year":"2017","unstructured":"Vitavska O, Wieczorek H (2017) Putative role of an SLC45 H(+)\/sugar cotransporter in mammalian spermatozoa. Pflug Arch: Eur J Physiol 469:1433\u20131442. https:\/\/doi.org\/10.1007\/s00424-017-2024-9","journal-title":"Pflug Arch: Eur J Physiol"},{"key":"11433_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.mam.2012.05.014","volume":"34","author":"O Vitavska","year":"2013","unstructured":"Vitavska O, Wieczorek H (2013) The SLC45 gene family of putative sugar transporters. Mol Aspects Med 34:655\u2013660. https:\/\/doi.org\/10.1016\/j.mam.2012.05.014","journal-title":"Mol Aspects Med"},{"key":"11433_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1158\/2159-8290.Cd-12-0212","volume":"2","author":"C Kumar-Sinha","year":"2012","unstructured":"Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM (2012) SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing. Cancer Discov 2:582\u2013585. https:\/\/doi.org\/10.1158\/2159-8290.Cd-12-0212","journal-title":"Cancer Discov"},{"key":"11433_CR4","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1091\/mbc.E20-03-0200","volume":"31","author":"L Le","year":"2020","unstructured":"Le L et al (2020) SLC45A2 protein stability and regulation of melanosome pH determine melanocyte pigmentation. Mol Biol Cell 31:2687\u20132702. https:\/\/doi.org\/10.1091\/mbc.E20-03-0200","journal-title":"Mol Biol Cell"},{"key":"11433_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09687688.2018.1448123","volume":"34","author":"X Bai","year":"2017","unstructured":"Bai X, Moraes TF, Reithmeier RA (2017) F. Structural biology of solute carrier (SLC) membrane transport proteins. Mol Membr Biol 34:1\u201332. https:\/\/doi.org\/10.1080\/09687688.2018.1448123","journal-title":"Mol Membr Biol"},{"key":"11433_CR6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ajhg.2017.03.009","volume":"100","author":"M Srour","year":"2017","unstructured":"Srour M et al (2017) Dysfunction of the cerebral glucose transporter SLC45A1 in individuals with intellectual disability and epilepsy. Am J Hum Genet 100:824\u2013830. https:\/\/doi.org\/10.1016\/j.ajhg.2017.03.009","journal-title":"Am J Hum Genet"},{"key":"11433_CR7","doi-asserted-by":"publisher","unstructured":"Wang Y (2021) Association of pigmentation related-genes polymorphisms and geographic environmental variables in the Chinese population. Hereditas 158 https:\/\/doi.org\/10.1186\/s41065-021-00189-7","DOI":"10.1186\/s41065-021-00189-7"},{"key":"11433_CR8","doi-asserted-by":"publisher","first-page":"183318","DOI":"10.1016\/j.bbamem.2020.183318","volume":"1862","author":"P Wiriyasermkul","year":"2020","unstructured":"Wiriyasermkul P, Moriyama S, Nagamori S (2020) Membrane transport proteins in melanosomes: regulation of ions for pigmentation. Biochim Et Biophys Acta Biomembr 1862:183318. https:\/\/doi.org\/10.1016\/j.bbamem.2020.183318","journal-title":"Biochim Et Biophys Acta Biomembr"},{"key":"11433_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12957-025-03805-2","volume":"23","author":"W Yan","year":"2025","unstructured":"Yan W, Wang H, Zhao Y, Zhang W, Li Y (2025) The PVT1-214\/miR-671-5p\/SLC45A4 signaling axis regulates cell proliferation in human gastric cancer. World J Surg Oncol 23:158. https:\/\/doi.org\/10.1186\/s12957-025-03805-2","journal-title":"World J Surg Oncol"},{"key":"11433_CR10","doi-asserted-by":"publisher","first-page":"9160","DOI":"10.1523\/jneurosci.22-21-09160.2002","volume":"22","author":"N Shimokawa","year":"2002","unstructured":"Shimokawa N et al (2002) Past-A, a novel proton-associated sugar transporter, regulates glucose homeostasis in the brain. J Neuroscience: Official J Soc Neurosci 22:9160\u20139165. https:\/\/doi.org\/10.1523\/jneurosci.22-21-09160.2002","journal-title":"J Neuroscience: Official J Soc Neurosci"},{"key":"11433_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/cge.14588","volume":"106","author":"C Zhou","year":"2024","unstructured":"Zhou C et al (2024) Compound heterozygous variants in SLC45A1 might cause syndromic intellectual disability by localization failure and activity Attenuation in cells. Clin Genet 106:638\u2013643. https:\/\/doi.org\/10.1111\/cge.14588","journal-title":"Clin Genet"},{"key":"11433_CR12","doi-asserted-by":"publisher","unstructured":"Carb\u00f3 R, Rodr\u00edguez E (2023) Relevance of sugar transport across the cell membrane. Int J Mol Sci 24 https:\/\/doi.org\/10.3390\/ijms24076085","DOI":"10.3390\/ijms24076085"},{"key":"11433_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/epi4.12899","volume":"9","author":"T Song","year":"2024","unstructured":"Song T et al (2024) Long-term effectiveness and tolerability of ketogenic diet therapy in patients with genetic developmental and epileptic encephalopathy onset within the first 6 months of life. Epilepsia Open 9:643\u2013652. https:\/\/doi.org\/10.1002\/epi4.12899","journal-title":"Epilepsia Open"},{"key":"11433_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ymgmr.2016.12.008","volume":"10","author":"S Nakamura","year":"2017","unstructured":"Nakamura S et al (2017) Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome. Mol Genet Metabolism Rep 10:67\u201374. https:\/\/doi.org\/10.1016\/j.ymgmr.2016.12.008","journal-title":"Mol Genet Metabolism Rep"},{"key":"11433_CR15","doi-asserted-by":"publisher","DOI":"10.1055\/a-2627-2097","author":"B Semal","year":"2025","unstructured":"Semal B et al (2025) Solute carrier 45A1: A new cerebral glucose transporter brain disorder with focal refractory epilepsy responsive to ketogenic diet and Acetazolamide. Neuropediatrics. https:\/\/doi.org\/10.1055\/a-2627-2097","journal-title":"Neuropediatrics"},{"key":"11433_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jconrel.2016.05.052","volume":"235","author":"CY Lin","year":"2016","unstructured":"Lin CY et al (2016) Non-invasive, neuron-specific gene therapy by focused ultrasound-induced blood-brain barrier opening in parkinson\u2019s disease mouse model. J Controlled Release: Official J Controlled Release Soc 235:72\u201381. https:\/\/doi.org\/10.1016\/j.jconrel.2016.05.052","journal-title":"J Controlled Release: Official J Controlled Release Soc"},{"key":"11433_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/2024.12.07.627366","author":"C Duan","year":"2024","unstructured":"Duan C et al (2024) One-Size-Fits-Many: antisense oligonucleotides for rescuing splicing mutations in hotspot exons. BioRxiv: Preprint Serv Biology. https:\/\/doi.org\/10.1101\/2024.12.07.627366","journal-title":"BioRxiv: Preprint Serv Biology"},{"key":"11433_CR18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/s1474-4422(15)00199-4","volume":"14","author":"A roadmap for precision medicine in the epilepsies","year":"2015","unstructured":"A roadmap for precision medicine in the epilepsies (2015) Lancet Neurol 14:1219\u20131228. https:\/\/doi.org\/10.1016\/s1474-4422(15)00199-4","journal-title":"Lancet Neurol"},{"key":"11433_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/14737175.2017.1253476","volume":"17","author":"PS Reif","year":"2017","unstructured":"Reif PS, Tsai MH, Helbig I, Rosenow F, Klein KM (2017) Precision medicine in genetic epilepsies: break of dawn? Expert Rev Neurother 17:381\u2013392. https:\/\/doi.org\/10.1080\/14737175.2017.1253476","journal-title":"Expert Rev Neurother"},{"key":"11433_CR20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1086\/324340","volume":"69","author":"JM Newton","year":"2001","unstructured":"Newton JM et al (2001) Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism, OCA4. Am J Hum Genet 69:981\u2013988. https:\/\/doi.org\/10.1086\/324340","journal-title":"Am J Hum Genet"},{"key":"11433_CR21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1086\/382195","volume":"74","author":"K Inagaki","year":"2004","unstructured":"Inagaki K et al (2004) Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. Am J Hum Genet 74:466\u2013471. https:\/\/doi.org\/10.1086\/382195","journal-title":"Am J Hum Genet"},{"key":"11433_CR22","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1016\/j.jid.2022.04.008","volume":"142","author":"Y Liu","year":"2022","unstructured":"Liu Y et al (2022) Ablation of Proton\/Glucose exporter SLC45A2 enhances melanosomal Glycolysis to inhibit melanin biosynthesis and promote melanoma metastasis. J Invest Dermatol 142:2744\u20132755e2749. https:\/\/doi.org\/10.1016\/j.jid.2022.04.008","journal-title":"J Invest Dermatol"},{"key":"11433_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/pcmr.12053","volume":"26","author":"CM Dooley","year":"2013","unstructured":"Dooley CM et al (2013) Slc45a2 and V-ATPase are regulators of melanosomal pH homeostasis in zebrafish, providing a mechanism for human pigment evolution and disease. Pigment Cell Melanoma Res 26:205\u2013217. https:\/\/doi.org\/10.1111\/pcmr.12053","journal-title":"Pigment Cell Melanoma Res"},{"key":"11433_CR24","doi-asserted-by":"publisher","first-page":"e47398","DOI":"10.1371\/journal.pone.0047398","volume":"7","author":"ZR Tsetskhladze","year":"2012","unstructured":"Tsetskhladze ZR et al (2012) Functional assessment of human coding mutations affecting skin pigmentation using zebrafish. PLoS ONE 7:e47398. https:\/\/doi.org\/10.1371\/journal.pone.0047398","journal-title":"PLoS ONE"},{"key":"11433_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/humu.20804","volume":"29","author":"LP Fernandez","year":"2008","unstructured":"Fernandez LP et al (2008) SLC45A2: a novel malignant melanoma-associated gene. Hum Mutat 29:1161\u20131167. https:\/\/doi.org\/10.1002\/humu.20804","journal-title":"Hum Mutat"},{"key":"11433_CR26","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/humu.20823","volume":"29","author":"M Guedj","year":"2008","unstructured":"Guedj M et al (2008) Variants of the MATP\/SLC45A2 gene are protective for melanoma in the French population. Hum Mutat 29:1154\u20131160. https:\/\/doi.org\/10.1002\/humu.20823","journal-title":"Hum Mutat"},{"key":"11433_CR27","doi-asserted-by":"publisher","first-page":"e104367","DOI":"10.1371\/journal.pone.0104367","volume":"9","author":"S L\u00f3pez","year":"2014","unstructured":"L\u00f3pez S et al (2014) The interplay between natural selection and susceptibility to melanoma on allele 374F of SLC45A2 gene in a South European population. PLoS ONE 9:e104367. https:\/\/doi.org\/10.1371\/journal.pone.0104367","journal-title":"PLoS ONE"},{"key":"11433_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1006\/jhev.2000.0403","volume":"39","author":"NG Jablonski","year":"2000","unstructured":"Jablonski NG, Chaplin G (2000) The evolution of human skin coloration. J Hum Evol 39:57\u2013106. https:\/\/doi.org\/10.1006\/jhev.2000.0403","journal-title":"J Hum Evol"},{"key":"11433_CR29","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1158\/2326-6066.Cir-17-0051","volume":"5","author":"J Park","year":"2017","unstructured":"Park J et al (2017) SLC45A2: A melanoma antigen with high tumor selectivity and reduced potential for autoimmune toxicity. Cancer Immunol Res 5:618\u2013629. https:\/\/doi.org\/10.1158\/2326-6066.Cir-17-0051","journal-title":"Cancer Immunol Res"},{"key":"11433_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/s0749-2081(97)80007-1","volume":"13","author":"MC Fraser","year":"1997","unstructured":"Fraser MC, Goldstein AM, Tucker MA (1997) The genetics of melanoma. Semin Oncol Nurs 13:108\u2013114. https:\/\/doi.org\/10.1016\/s0749-2081(97)80007-1","journal-title":"Semin Oncol Nurs"},{"key":"11433_CR31","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/ncomms13404","volume":"7","author":"M Bassani-Sternberg","year":"2016","unstructured":"Bassani-Sternberg M et al (2016) Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 7:13404. https:\/\/doi.org\/10.1038\/ncomms13404","journal-title":"Nat Commun"},{"key":"11433_CR32","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1016\/j.ymthe.2025.05.036","volume":"33","author":"X Che","year":"2025","unstructured":"Che X et al (2025) Multi-engineered T cell vaccine boosting TCR-T cell therapy enhances anti-tumor function and eradicates heterogeneous solid tumors. Mol Therapy: J Am Soc Gene Therapy 33:4529\u20134551. https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.036","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"11433_CR33","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/0008-5472.Can-10-0118","volume":"70","author":"A Boni","year":"2010","unstructured":"Boni A et al (2010) Selective BRAFV600E Inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213\u20135219. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-0118","journal-title":"Cancer Res"},{"key":"11433_CR34","doi-asserted-by":"publisher","first-page":"1191262","DOI":"10.3389\/fphar.2023.1191262","volume":"14","author":"A Lavoro","year":"2023","unstructured":"Lavoro A et al (2023) In Silico analysis of the solute carrier (SLC) family in cancer indicates a link among DNA methylation, metabolic adaptation, drug response, and immune reactivity. Front Pharmacol 14:1191262. https:\/\/doi.org\/10.3389\/fphar.2023.1191262","journal-title":"Front Pharmacol"},{"key":"11433_CR35","doi-asserted-by":"publisher","unstructured":"Ren J et al (2023) A Chamber-based digital PCR based on a microfluidic chip for the absolute quantification and analysis of KRAS mutation. Biosensors 13 https:\/\/doi.org\/10.3390\/bios13080778","DOI":"10.3390\/bios13080778"},{"key":"11433_CR36","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1128\/jcm.02255-09","volume":"48","author":"C Bouakaze","year":"2010","unstructured":"Bouakaze C et al (2010) Identification and genotyping of Mycobacterium tuberculosis complex species by use of a snapshot Minisequencing-based assay. J Clin Microbiol 48:1758\u20131766. https:\/\/doi.org\/10.1128\/jcm.02255-09","journal-title":"J Clin Microbiol"},{"key":"11433_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/jamadermatol.2023.6251","volume":"160","author":"R Ghiasvand","year":"2024","unstructured":"Ghiasvand R, Green AC, Veier\u00f8d MB, Robsahm TE (2024) Incidence and factors associated with second primary invasive melanoma in Norway. JAMA Dermatology 160:402\u2013408. https:\/\/doi.org\/10.1001\/jamadermatol.2023.6251","journal-title":"JAMA Dermatology"},{"key":"11433_CR38","doi-asserted-by":"publisher","unstructured":"Strobel SB, Machiraju D, Hassel JC (2022) TCR-Directed therapy in the treatment of metastatic uveal melanoma. Cancers 14 https:\/\/doi.org\/10.3390\/cancers14051215","DOI":"10.3390\/cancers14051215"},{"key":"11433_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/mnm.0000000000000406","volume":"37","author":"RJ Schmitt","year":"2016","unstructured":"Schmitt RJ et al (2016) Correlation between early 18F-FDG PET\/CT response to BRAF and MEK Inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nucl Med Commun 37:122\u2013128. https:\/\/doi.org\/10.1097\/mnm.0000000000000406","journal-title":"Nucl Med Commun"},{"key":"11433_CR40","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1007\/s00330-021-08355-1","volume":"32","author":"A Annovazzi","year":"2022","unstructured":"Annovazzi A et al (2022) Prognostic value of total metabolic tumour volume and therapy-response assessment by [(18)F]FDG PET\/CT in patients with metastatic melanoma treated with BRAF\/MEK inhibitors. Eur Radiol 32:3398\u20133407. https:\/\/doi.org\/10.1007\/s00330-021-08355-1","journal-title":"Eur Radiol"},{"key":"11433_CR41","doi-asserted-by":"publisher","first-page":"e24075","DOI":"10.1371\/journal.pone.0024075","volume":"6","author":"L Milane","year":"2011","unstructured":"Milane L, Duan Z, Amiji M (2011) Therapeutic efficacy and safety of paclitaxel\/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS ONE 6:e24075. https:\/\/doi.org\/10.1371\/journal.pone.0024075","journal-title":"PLoS ONE"},{"key":"11433_CR42","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1021\/acs.nanolett.1c03089","volume":"21","author":"X Liu","year":"2021","unstructured":"Liu X et al (2021) GSH-Responsive nanoprodrug to inhibit Glycolysis and alleviate immunosuppression for cancer therapy. Nano Lett 21:7862\u20137869. https:\/\/doi.org\/10.1021\/acs.nanolett.1c03089","journal-title":"Nano Lett"},{"key":"11433_CR43","doi-asserted-by":"publisher","unstructured":"Merino M et al (2021) Dual activity of PD-L1 targeted doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. J Nanobiotechnol 19 https:\/\/doi.org\/10.1186\/s12951-021-00846-z","DOI":"10.1186\/s12951-021-00846-z"},{"key":"11433_CR44","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41417-021-00367-9","volume":"29","author":"M Barati","year":"2022","unstructured":"Barati M et al (2022) Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes. Cancer Gene Ther 29:814\u2013824. https:\/\/doi.org\/10.1038\/s41417-021-00367-9","journal-title":"Cancer Gene Ther"},{"key":"11433_CR45","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S (2023) Cancer immunotherapies: advances and bottlenecks. Front Immunol 14:1212476. https:\/\/doi.org\/10.3389\/fimmu.2023.1212476","journal-title":"Front Immunol"},{"key":"11433_CR46","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/0008-5472.Can-08-4926","volume":"69","author":"DS Rickman","year":"2009","unstructured":"Rickman DS et al (2009) SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 69:2734\u20132738. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-4926","journal-title":"Cancer Res"},{"key":"11433_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/0008-5472.Can-07-5352","volume":"68","author":"BE Helgeson","year":"2008","unstructured":"Helgeson BE et al (2008) Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 68:73\u201380. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-5352","journal-title":"Cancer Res"},{"key":"11433_CR48","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/ijc.27733","volume":"132","author":"S Perner","year":"2013","unstructured":"Perner S et al (2013) Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. Int J Cancer 132:807\u2013812. https:\/\/doi.org\/10.1002\/ijc.27733","journal-title":"Int J Cancer"},{"key":"11433_CR49","doi-asserted-by":"publisher","first-page":"188","DOI":"10.7150\/ijbs.50810","volume":"17","author":"W Liu","year":"2021","unstructured":"Liu W et al (2021) PRPF6 promotes androgen receptor\/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells. Int J Biol Sci 17:188\u2013203. https:\/\/doi.org\/10.7150\/ijbs.50810","journal-title":"Int J Biol Sci"},{"key":"11433_CR50","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s12975-023-01145-5","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y et al (2024) SLC45A3 serves as a potential therapeutic biomarker to attenuate white matter injury after intracerebral hemorrhage. Translational Stroke Res 15:556\u2013571. https:\/\/doi.org\/10.1007\/s12975-023-01145-5","journal-title":"Translational Stroke Res"},{"key":"11433_CR51","doi-asserted-by":"publisher","first-page":"115143","DOI":"10.1016\/j.expneurol.2025.115143","volume":"386","author":"S Gotoh","year":"2025","unstructured":"Gotoh S et al (2025) Intranasal administration of stem cell-derived exosome alleviates cognitive impairment against subarachnoid hemorrhage. Exp Neurol 386:115143. https:\/\/doi.org\/10.1016\/j.expneurol.2025.115143","journal-title":"Exp Neurol"},{"key":"11433_CR52","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1593\/neo.10726","volume":"12","author":"K Park","year":"2010","unstructured":"Park K et al (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (New York N Y) 12:590\u2013598. https:\/\/doi.org\/10.1593\/neo.10726","journal-title":"Neoplasia (New York N Y)"},{"key":"11433_CR53","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/mt.2011.164","volume":"19","author":"X Zhuang","year":"2011","unstructured":"Zhuang X et al (2011) Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Therapy: J Am Soc Gene Therapy 19:1769\u20131779. https:\/\/doi.org\/10.1038\/mt.2011.164","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"11433_CR54","doi-asserted-by":"publisher","first-page":"8987","DOI":"10.2147\/ijn.S473611","volume":"19","author":"S Jiang","year":"2024","unstructured":"Jiang S et al (2024) Novel therapeutic mechanisms and strategies for intracerebral hemorrhage: focusing on exosomes. Int J Nanomed 19:8987\u20139007. https:\/\/doi.org\/10.2147\/ijn.S473611","journal-title":"Int J Nanomed"},{"key":"11433_CR55","doi-asserted-by":"publisher","first-page":"e3364","DOI":"10.1002\/jgm.3364","volume":"23","author":"W Chen","year":"2021","unstructured":"Chen W et al (2021) SLC45A4 promotes Glycolysis and prevents AMPK\/ULK1-induced autophagy in TP53 mutant pancreatic ductal adenocarcinoma. J Gene Med 23(e3364) https:\/\/doi.org\/10.1002\/jgm.3364","journal-title":"J Gene Med"},{"key":"11433_CR56","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/s41598-022-05341-5","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang J, Zhang A, Luo H, Ma C (2022) Construction and validation of a novel gene signature for predicting the prognosis of osteosarcoma. Sci Rep 12:1279. https:\/\/doi.org\/10.1038\/s41598-022-05341-5","journal-title":"Sci Rep"},{"key":"11433_CR57","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/387296a0","volume":"387","author":"Y Haupt","year":"1997","unstructured":"Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296\u2013299. https:\/\/doi.org\/10.1038\/387296a0","journal-title":"Nature"},{"key":"11433_CR58","doi-asserted-by":"publisher","first-page":"23031","DOI":"10.1038\/s41598-024-74249-z","volume":"14","author":"Y Xu","year":"2024","unstructured":"Xu Y et al (2024) SLC45A4 is involved in malignant progression of ovarian cancer through glycolytic metabolic reprogramming. Sci Rep 14:23031. https:\/\/doi.org\/10.1038\/s41598-024-74249-z","journal-title":"Sci Rep"},{"key":"11433_CR59","doi-asserted-by":"publisher","unstructured":"Majuelos-Melguizo J et al (2022) Glioblastoma cells counteract PARP Inhibition through Pro-Survival induction of lipid droplets synthesis and utilization. Cancers 14 https:\/\/doi.org\/10.3390\/cancers14030726","DOI":"10.3390\/cancers14030726"},{"key":"11433_CR60","doi-asserted-by":"publisher","unstructured":"Sun C et al (2020) MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC. J Hematol Oncol 13 https:\/\/doi.org\/10.1186\/s13045-020-0844-0","DOI":"10.1186\/s13045-020-0844-0"},{"key":"11433_CR61","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang Z et al (2019) Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep 9:1853. https:\/\/doi.org\/10.1038\/s41598-019-38534-6","journal-title":"Sci Rep"},{"key":"11433_CR62","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1055\/a-2627-2097","volume":"56","author":"B Semal","year":"2025","unstructured":"Semal B et al (2025) Solute carrier 45A1: A new cerebral glucose transporter brain disorder with focal refractory epilepsy responsive to ketogenic diet and Acetazolamide. Neuropediatrics 56:342\u2013346. https:\/\/doi.org\/10.1055\/a-2627-2097","journal-title":"Neuropediatrics"},{"key":"11433_CR63","doi-asserted-by":"publisher","first-page":"704","DOI":"10.4103\/nrr.Nrr-d-23-01802","volume":"21","author":"R Shi","year":"2026","unstructured":"Shi R et al (2026) Tropism-shifted AAV-PHP.eB-mediated bFGF gene therapy promotes varied neurorestoration after ischemic stroke in mice. Neural Regeneration Res 21:704\u2013714. https:\/\/doi.org\/10.4103\/nrr.Nrr-d-23-01802","journal-title":"Neural Regeneration Res"},{"key":"11433_CR64","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000513336","volume":"7","author":"M Orloff","year":"2021","unstructured":"Orloff M (2021) Clinical trials in metastatic uveal melanoma: immunotherapy. Ocular Oncol Pathol 7:168\u2013176. https:\/\/doi.org\/10.1159\/000513336","journal-title":"Ocular Oncol Pathol"},{"key":"11433_CR65","doi-asserted-by":"publisher","unstructured":"Fu Y, Xiao W, Mao Y (2022) Recent advances and challenges in uveal melanoma immunotherapy. Cancers 14 https:\/\/doi.org\/10.3390\/cancers14133094","DOI":"10.3390\/cancers14133094"},{"key":"11433_CR66","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028\u20131038. https:\/\/doi.org\/10.1056\/NEJMoa1315815","journal-title":"N Engl J Med"},{"key":"11433_CR67","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neuroscience.2012.03.054","volume":"213","author":"D Shin","year":"2012","unstructured":"Shin D, Howng SY, Pt\u00e1\u010dek LJ, Fu YH (2012) miR-32 and its target SLC45A3 regulate the lipid metabolism of oligodendrocytes and Myelin. Neuroscience 213:29\u201337. https:\/\/doi.org\/10.1016\/j.neuroscience.2012.03.054","journal-title":"Neuroscience"},{"key":"11433_CR68","first-page":"1837","volume":"8","author":"B Shao","year":"2018","unstructured":"Shao B et al (2018) Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. Am J Cancer Res 8:1837\u20131846","journal-title":"Am J Cancer Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11433-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11433-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11433-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:54:08Z","timestamp":1768474448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11433-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11433"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11433-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The author(s) declared that no Generative AI was used in the creation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI statement"}}],"article-number":"279"}}